The Dow Chemical Company, et al.; Proposed Consent Agreement With Analysis To Aid Public Comment

Resumo

In settlement of alleged violations of federal law prohibiting unfair acts and practices and unfair methods of competition, this consent agreement, accepted subject to final Commission approval, would require, among other things, Marion Merrell Dow to license its dicyclomine formulations and production technology to a third party, and to contract manufacture dicyclomine for the third party while that party awaits the Food and Drug Administration approval to sell its own dicyclomine. The consent agreement also would prohibit future acquisition of any dicyclomine manufacturing, production or distribution capabilities without prior Commission approval.